Xenon Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| XENE | PRAX | JAZZ | SANION.ST | ATAI | RAPP | |
|---|---|---|---|---|---|---|
| Market cap | 3.80B | 7.95B | 15.06B | 1.53B | — | 1.50B |
| P/E (TTM) | — | — | 69.4 | 8.6 | — | — |
| Forward P/E | -8.3 | -30.0 | 9.1 | — | — | -5.1 |
| Price/book | 3.1 | 5.9 | 3.6 | 2.8 | — | 3.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +2.32% | +65.24% | +75.05% | −36.20% | — | +2.25% |
| Today | +2.51% | +1.53% | +2.14% | +3.45% | 0.00% | +1.93% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All XENE news ›Xenon Pharmaceuticals (XENE) Set to Post Quarterly Earnings on Monday
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) is expected to issue its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to post earnings of ($1.13) per share and revenue of $1.33 million…
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
October 20, 2026 20:50 ET | Source: Wolf Popper LLP Wolf Popper LLP NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing its investigation into potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc.…
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Xenon Pharmaceuticals XENE is facing investor concerns after a safety-related setback in its late-stage depression program. The company is evaluating its lead pipeline asset, azetukalner, in phase III X-NOVA2 and X-NOVA3 studies for the…
Technical Reactions to XENE Trends in Macro Strategies
Stock Traders Daily Key findings for Xenon Pharmaceuticals Inc. (NASDAQ: XENE) - Weak Near and Mid-Term Sentiment Could Challenge Long-Term Positive Outlook - Elevated downside risk as no additional long-term support signals remain. -…
Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)
Posted by Kim Johansen on Oct 12th, 2026 Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) and United Therapeutics (NASDAQ:UTHR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the…
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low – Here’s Why
Posted by Tristan Rich on Oct 6th, 2026 Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $36.02 and last traded at $35.9350, with a volume…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- globenewswire.com2
- themarketsdaily.com2
- defenseworld.net1
- news.stocktradersdaily.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.